Quick Answer
GT Biopharma, Inc. reported Cash and Equivalents of $6.81 million for fiscal year 2025.
GT Biopharma, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $6.81M | +72.4% |
| 2024 | $3.95M | +266.2% |
| 2023 | $1.08M | -81.0% |
| 2022 | $5.67M | -36.8% |
| 2021 | $8.97M | +69.3% |
| 2020 | $5.30M | +18817.9% |
| 2019 | $28.0K | -53.3% |
| 2018 | $60.0K | -89.6% |
| 2017 | $576.0K | +2931.6% |
| 2016 | $19.0K | -59.6% |
| 2015 | $47.0K | -94.5% |
| 2014 | $855.0K | +1888.4% |
| 2013 | $43.0K | -65.0% |
| 2012 | $123.0K | +101.6% |
| 2012 | $61.0K | -33.7% |
| 2011 | $92.0K | +70.4% |
| 2010 | $54.0K | -95.8% |
| 2009 | $1.29M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.53M | -60.6% | -51.6% |
| June 30, 2025 | $5.23M | -43.5% | +121.1% |
| March 31, 2025 | $2.37M | +21.3% | -40.1% |
| December 31, 2024 | $3.95M | +266.2% | -38.4% |
| September 30, 2024 | $6.42M | +142.4% | -30.6% |
| June 30, 2024 | $9.25M | +234.3% | +374.3% |
| March 31, 2024 | $1.95M | -4.6% | +80.7% |
| December 31, 2023 | $1.08M | -81.0% | -59.3% |
- GT Biopharma, Inc. showed an increase of +72.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2009–2025 period, GT Biopharma, Inc.’s cash and equivalents has grown by 426.8% (from $1.29 million to $6.81 million).
- The most recent figure is from GT Biopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: